HBM1020

Harbour BioMed US, Inc. · Phase 1 active Small molecule

At a glance

Generic name	HBM1020
Sponsor	Harbour BioMed US, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HBM1020 CI brief — competitive landscape report
HBM1020 updates RSS · CI watch RSS
Harbour BioMed US, Inc. portfolio CI